NCT06064500 2025-03-10Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerAmgenApproved for marketing
NCT04507919 2024-11-12Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNovartisNo longer available
NCT04504513 2021-03-19Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerG1 Therapeutics, Inc.Approved for marketing
NCT04291937 2020-06-19A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USAJazz PharmaceuticalsApproved for marketing